We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New Landmark Study Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients

By HospiMedica International staff writers
Posted on 27 Oct 2020
A new landmark study has found that hospitalized patients who were taking daily aspirin had lower risk of ICU admission, ventilation, and dying from the SARS-CoV-2 virus

The study led by researchers at the University of Maryland School of Medicine (Baltimore, MD, USA) found that hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin. More...
Aspirin takers were less likely to be placed in the intensive care unit (ICU) or hooked up to a mechanical ventilator, and they were more likely to survive the infection compared to hospitalized patients who were not taking aspirin. The study provides “cautious optimism” for an inexpensive, accessible medication with a well-known safety profile that could help prevent severe complications, according to the researchers.

To conduct the study, the researchers culled through the medical records of 412 COVID-19 patients, age of 55 on average, who were hospitalized over the past few months due to complications of their infection. About a quarter of the patients were taking a daily low-dose aspirin (usually 81 milligrams) before they were admitted or right after admission to manage their cardiovascular disease. The researchers found aspirin use was associated with a 44% reduction in the risk of being put on a mechanical ventilator, a 43% decrease in the risk of ICU admission and most importantly, a 47% decrease in the risk of dying in the hospital compared to those who were not taking aspirin. The patients in the aspirin group did not experience a significant increase in adverse events such as major bleeding while hospitalized.

“This is a critical finding that needs to be confirmed through a randomized clinical trial,” said study leader Jonathan Chow, MD, Assistant Professor of Anesthesiology at UMSOM. “If our finding is confirmed, it would make aspirin the first widely available, over-the-counter medication to reduce mortality in COVID-19 patients.”

“We believe that the blood thinning effects of aspirin provides benefits for COVID-19 patients by preventing microclot formation,” said study co-author Michael A. Mazzeffi, MD, Associate Professor of Anesthesiology at UMSOM. “Patients diagnosed with COVID-19 may want to consider taking a daily aspirin as long as they check with their doctor first.”

Related Links:
University of Maryland School of Medicine


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Medical-Grade Display
HL2316SHTB
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Masimo smartSET pulse oximetry with PPG AFib and OIRD Detection (Photo courtesy of Masimo)

Smart Pulse Oximetry Supports Earlier Recognition of Arrhythmias and Respiratory Risk

On general care floors, respiratory compromise and arrhythmias can develop between routine checks. Atrial fibrillation often goes undiagnosed in older adults, while opioid-induced respiratory depression... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Medical Imaging

view channel
Image: Visual Abstract (Sinuo Gao, Zhaoqi Zhang, Chao Shi, Cheng Cheng, Xindi Ma, Xinming Zhao, Yunjiang Liu Journal of Nuclear Medicine Oct 2026, 67 (10) 1552-1559; DOI: 10.2967/jnumed.125.271529)

Targeted PET/CT Predicts Early Treatment Response in HER2-Positive Breast Cancer

HER2-positive breast cancer is an aggressive subtype that accounts for a substantial proportion of breast cancer cases. Patients often receive neoadjuvant therapy before surgery to shrink tumors, but assessing... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.